Terms: = Ovarian epithelial cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Prognosis
189 results:
1. STEAP3 Affects ovarian cancer Progression by Regulating Ferroptosis through the p53/SLC7A11 Pathway.
Han Y; Fu L; Kong Y; Jiang C; Huang L; Zhang H
Mediators Inflamm; 2024; 2024():4048527. PubMed ID: 38440354
[TBL] [Abstract] [Full Text] [Related]
2. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
3. Genomic and Molecular Characteristics of ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract] [Full Text] [Related]
4. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
Heinzl N; Maritschnegg E; Koziel K; Schilhart-Wallisch C; Heinze G; Yang WL; Bast RC; Sehouli J; Braicu EI; Vergote I; Van Gorp T; Mahner S; Paspalj V; Grimm C; Obermayr E; Schuster E; Holzer B; Rousseau F; Schymkowitz J; Concin N; Zeillinger R
Oncogene; 2023 Aug; 42(33):2473-2484. PubMed ID: 37402882
[TBL] [Abstract] [Full Text] [Related]
5. KLF5-mediated CDCA5 expression promotes tumor development and progression of epithelial ovarian carcinoma.
Chen X; Zhou M; Ma S; Wu H; Cai H
Exp Cell Res; 2023 Aug; 429(1):113645. PubMed ID: 37247719
[TBL] [Abstract] [Full Text] [Related]
6. Genetic analysis for mucinous ovarian carcinoma with infiltrative and expansile invasion and mucinous borderline tumor: a retrospective analysis.
Hada T; Miyamoto M; Ohtsuka Y; Suminokura J; Ito T; Kishimoto N; Nishitani S; Takada M; Imauji A; Tanabe R; Takano M
Diagn Pathol; 2023 Apr; 18(1):49. PubMed ID: 37081552
[TBL] [Abstract] [Full Text] [Related]
7. p53 and ovarian carcinoma survival: an ovarian Tumor Tissue Analysis consortium study.
Köbel M; Kang EY; Weir A; Rambau PF; Lee CH; Nelson GS; Ghatage P; Meagher NS; Riggan MJ; Alsop J; Anglesio MS; Beckmann MW; Bisinotto C; Boisen M; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; Deen S; El-Bahrawy MA; Elishaev E; Erber R; Fereday S; ; Fischer A; Gayther SA; Barquin-Garcia A; Gentry-Maharaj A; Gilks CB; Gronwald H; Grube M; Harnett PR; Harris HR; Hartkopf AD; Hartmann A; Hein A; Hendley J; Hernandez BY; Huang Y; Jakubowska A; Jimenez-Linan M; Jones ME; Kennedy CJ; Kluz T; Koziak JM; Lesnock J; Lester J; Lubiński J; Longacre TA; Lycke M; Mateoiu C; McCauley BM; McGuire V; Ney B; Olawaiye A; Orsulic S; Osorio A; Paz-Ares L; Ramón Y Cajal T; Rothstein JH; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Singh N; Steed H; Storr SJ; Talhouk A; Traficante N; Wang C; Whittemore AS; Widschwendter M; Wilkens LR; Winham SJ; Benitez J; Berchuck A; Bowtell DD; Candido Dos Reis FJ; Campbell I; Cook LS; DeFazio A; Doherty JA; Fasching PA; Fortner RT; García MJ; Goodman MT; Goode EL; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Kommoss S; Le ND; Martin SG; Menon U; Modugno F; Pharoah PD; Schildkraut JM; Sieh W; Staebler A; Sundfeldt K; Swerdlow AJ; Ramus SJ; Brenton JD
J Pathol Clin Res; 2023 May; 9(3):208-222. PubMed ID: 36948887
[TBL] [Abstract] [Full Text] [Related]
8. L1-CAM in Mucinous ovarian Carcinomas and Borderline Tumors: Impact on Tumor Recurrence and Potential Role in Tumor Progression.
Wiedenhoefer R; Schmoeckel E; Grube M; Sulyok M; Pasternak I; Beschorner C; Greif K; Brucker S; Mayr D; Kommoss S; Fend F; Staebler A; Fischer AK
Am J Surg Pathol; 2023 May; 47(5):558-567. PubMed ID: 36852510
[TBL] [Abstract] [Full Text] [Related]
9. Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.
Yoshida-Court K; Karpinets TV; Mitra A; Solley TN; Dorta-Estremera S; Sims TT; Delgado Medrano AY; El Alam MB; Ahmed-Kaddar M; Lynn EJ; Sastry KJ; Zhang J; Futreal A; Nick A; Lu K; Colbert LE; Klopp AH
PLoS One; 2023; 18(1):e0279590. PubMed ID: 36607962
[TBL] [Abstract] [Full Text] [Related]
10. Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition.
Tocci P; Roman C; Sestito R; Di Castro V; Sacconi A; Molineris I; Paolini F; Carosi M; Tonon G; Blandino G; Bagnato A
Cell Death Dis; 2023 Jan; 14(1):5. PubMed ID: 36604418
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Management of High-Grade Serous ovarian Carcinoma.
Punzón-Jiménez P; Lago V; Domingo S; Simón C; Mas A
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430255
[TBL] [Abstract] [Full Text] [Related]
12. MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate ovarian cancer Tumorigenesis.
Wang CK; Chen TJ; Tan GYT; Chang FP; Sridharan S; Yu CA; Chang YH; Chen YJ; Cheng LT; Hwang-Verslues WW
Cancer Res; 2023 Jan; 83(2):251-263. PubMed ID: 36354374
[TBL] [Abstract] [Full Text] [Related]
13. ovarian Mucinous Carcinoma with a Yolk sac Tumor-Like Component: A Report of Three Cases with a Literature Review for Prognostic Analysis.
Tsujimura M; Fujimoto M; Minamiguchi S; Miyamoto T; Ueda A; Hamanishi J; Mandai M; Haga H
Int J Surg Pathol; 2023 Aug; 31(5):765-771. PubMed ID: 36314449
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Evidence for epithelial Origin of Mixed ovarian epithelial-Germ Cell Neoplasms: Report of 2 Cases and Review of Literature.
Hall KC; Post MD; Alldredge J; Aisner DL; Berning A
Int J Gynecol Pathol; 2023 Jul; 42(4):403-413. PubMed ID: 36305517
[TBL] [Abstract] [Full Text] [Related]
15. IDO1 Modulates the Sensitivity of epithelial ovarian cancer Cells to Cisplatin through ROS/p53-Dependent Apoptosis.
Wang H; Luo Y; Ran R; Li X; Ling H; Wen F; Yu T
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233312
[TBL] [Abstract] [Full Text] [Related]
16. Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.
Hlaváč V; Holý P; Václavíková R; Rob L; Hruda M; Mrhalová M; Černaj P; Bouda J; Souček P
Life Sci Alliance; 2022 Oct; 5(12):. PubMed ID: 36229065
[TBL] [Abstract] [Full Text] [Related]
17. Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells.
Alzahrani A; Natarajan U; Rathinavelu A
Cancer Genet; 2022 Aug; 266-267():57-68. PubMed ID: 35785714
[TBL] [Abstract] [Full Text] [Related]
18. Identification and clinical validation of NUSAP1 as a novel prognostic biomarker in ovarian cancer.
Gou R; Zheng M; Hu Y; Gao L; Wang S; Liu O; Li X; Zhu L; Liu J; Lin B
BMC Cancer; 2022 Jun; 22(1):690. PubMed ID: 35739489
[TBL] [Abstract] [Full Text] [Related]
19. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
[TBL] [Abstract] [Full Text] [Related]
20. Association between miR-196a-2 Gene Polymorphism and ovarian cancer prognosis in Egyptian Females.
Hussein S; Lasheen AES; Abdelrahman AA; Al-Karamany AS; Sameh R; Algazeery A
Asian Pac J Cancer Prev; 2022 May; 23(5):1761-1768. PubMed ID: 35633562
[TBL] [Abstract] [Full Text] [Related]
[Next]
